264 related articles for article (PubMed ID: 16399579)
1. Vaccination for leukemia.
Molldrem JJ
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):13-8. PubMed ID: 16399579
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic peptide vaccination with leukemia-associated antigens.
Rusakiewicz S; Molldrem JJ
Curr Opin Immunol; 2006 Oct; 18(5):599-604. PubMed ID: 16870418
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.
Hofmann S; Greiner J
Leuk Res; 2010 Jul; 34(7):850-1. PubMed ID: 20359745
[TBL] [Abstract][Full Text] [Related]
4. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
5. Current status of vaccination therapy for leukemias.
Reichardt VL; Brossart P
Curr Hematol Rep; 2005 Jan; 4(1):73-6. PubMed ID: 15610663
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of chronic myeloid leukemia: present state and future prospects.
Vonka V
Immunotherapy; 2010 Mar; 2(2):227-41. PubMed ID: 20635930
[TBL] [Abstract][Full Text] [Related]
9. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
Greiner J; Schmitt M
Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627
[TBL] [Abstract][Full Text] [Related]
10. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.
Schwartz J; Pinilla-Ibarz J; Yuan RR; Scheinberg DA
Semin Hematol; 2003 Jan; 40(1):87-96. PubMed ID: 12563615
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
13. The promise of T-lymphocyte immunotherapy for the treatment of malignant disease.
Thomas AK; June CH
Cancer J; 2001; 7 Suppl 2():S67-75. PubMed ID: 11777267
[TBL] [Abstract][Full Text] [Related]
14. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
15. Rational peptide-based tumour vaccine development and T cell monitoring.
Scheibenbogen C; Letsch A; Schmittel A; Asemissen AM; Thiel E; Keilholz U
Semin Cancer Biol; 2003 Dec; 13(6):423-9. PubMed ID: 15001161
[TBL] [Abstract][Full Text] [Related]
16. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
Haining WN; Cardoso AA; Keczkemethy HL; Fleming M; Neuberg D; DeAngelo DJ; Stone RM; Galinsky I; Silverman LB; Sallan SE; Nadler LM; Guinan EC
Exp Hematol; 2005 Mar; 33(3):286-94. PubMed ID: 15730852
[TBL] [Abstract][Full Text] [Related]
17. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
18. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
19. Definition of immunogenic antigens in chronic myeloid leukemia (CML) towards the development of cancer vaccines.
Schmitt M; Greiner J
Leuk Res; 2005 Dec; 29(12):1367-9. PubMed ID: 16135383
[No Abstract] [Full Text] [Related]
20. [Immunotherapy and cell therapy for myeloid leukemia].
Yasukawa M
Nihon Rinsho; 2009 Oct; 67(10):1938-43. PubMed ID: 19860194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]